RapaLink-1 outperforms rapamycin in alleviating allogeneic graft rejection by inhibiting the mTORC1-4E-BP1 pathway in mice
International Immunopharmacology · 2023-12 · 125 · 111172
DOI: 10.1016/j.intimp.2023.111172 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-12. Verfasst von Ning Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangz…. Hauptthemen laut MEDLINE: MTOR Inhibitors, Sirolimus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases.
Abstract (Originalsprache)
Inhibition of mammalian target of rapamycin (mTOR), which is a component of both mTORC1 and mTORC2, leads to clinical benefits for organ transplant recipients. Pathways to inhibit mTOR include strengthening the association of FKBP12-mTOR or competing with ATP at the active site of mTOR, which have been applied to the design of first- and second-generation mTOR inhibitors, respectively. However, the clinical efficacy of these mTOR inhibitors may be limited by side effects, compensatory activation of kinases and attenuation of feedback inhibition of receptor expression. A new generation of mTOR inhibitors possess a core structure similar to rapamycin and covalently link to mTOR kinase inhibitors, resulting in moderate selectivity and potent inhibition of mTORC1. Since the immunosuppressive potential of this class of compounds remains unknown, our goal is to examine the therapeutic efficacy of a third-generation mTOR inhibitor in organ transplantation. In this study, RapaLink-1 outperformed rapamycin in inhibiting T-cell proliferation and significantly prolonged graft survival time. Mechanistically, the ameliorated rejection induced by RapaLink-1 is associated with a reduction in p-4E-BP1 in T cells, resulting in an elevation in Treg cells alongside a decline in Th1 and Th17 cells. For the first time, these studies demonstrate the effectiveness of third-generation mTOR inhibitors in inhibiting allograft rejection, highlighting the potential of this novel class of mTOR inhibitors for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
- Division of Lung Transplantation and Thoracic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
- College of Pharmaceutical Sciences, Zhejiang University, 310058 Hangzhou, China.
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Key Laboratory of the Diagnosis and Treatment of Or…
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
Zitieren
APA
Wang, N., Zhou, K., Liang, Z., Sun, R., Tang, H., Yang, Z., Zhao, W., Peng, Y., Song, P., Zheng, S., & Xie, H. (2023). RapaLink-1 outperforms rapamycin in alleviating allogeneic graft rejection by inhibiting the mTORC1-4E-BP1 pathway in mice. International Immunopharmacology, 125, 111172. https://doi.org/10.1016/j.intimp.2023.111172
Vancouver
Wang N, Zhou K, Liang Z, Sun R, Tang H, Yang Z, et al. RapaLink-1 outperforms rapamycin in alleviating allogeneic graft rejection by inhibiting the mTORC1-4E-BP1 pathway in mice. International Immunopharmacology. 2023;125:111172. doi:10.1016/j.intimp.2023.111172
BibTeX
@article{Wang2023,
author = {Wang, Ning and Zhou, Ke and Liang, Zhi and Sun, Ruiqi and Tang, Hong and Yang, Zhentao and Zhao, Wentao and Peng, Yiyang and Song, Penghong and Zheng, Shusen and Xie, Haiyang},
title = {RapaLink-1 outperforms rapamycin in alleviating allogeneic graft rejection by inhibiting the mTORC1-4E-BP1 pathway in mice},
journal = {International Immunopharmacology},
year = {2023},
volume = {125},
pages = {111172},
doi = {10.1016/j.intimp.2023.111172}
}
EUVIMED